Company / PP&E per Share
Fulcrum Therapeutics, Inc. PP&E per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E per Share
$44.57
FY2025
5-year range
$44.57 / $208.37
FY2021-FY2025
Trend
-29.2%
vs FY2024
Sector context
#3 of 191
Health Care
What the data says
Among 191 Health Care companies, Fulcrum Therapeutics, Inc. is in the top 2% for pp&e per share. PP&E per Share has declined for 7 consecutive years, from $8389.82 in FY2018 to $44.57 in FY2025.
Based on SEC 10-K filings.
44.57 in FY2025 with a 5-year CAGR of -33.0%. Ranks 3rd among 191 companies in Health Care.
Declined from $85.08 to $44.57 over the past 2 years.
Health Care sector context is included.
PP&E per Share over time
Growth rates
- 3-Year CAGR
- -33.8%
- 5-Year CAGR
- -33.0%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 191This company $44.57 Sector average $22.34
▼
+99.5% above sector average
Key checks
Key Insights
- Fulcrum Therapeutics, Inc.'s pp&e per share has declined for 7 consecutive years.
- In FY2025, pp&e per share decreased 29.2% year-over-year.
- Ranks #3 out of 191 companies in the Health Care sector.
- Peak pp&e per share was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.57 | -29.2% |
| FY2024 | $62.92 | -26.0% |
| FY2023 | $85.08 | -44.6% |
| FY2022 | $153.50 | -26.3% |
| FY2021 | $208.37 | -37.1% |
| FY2020 | $331.19 | -60.3% |
| FY2019 | $833.33 | -90.1% |
| FY2018 | $8389.82 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026